At Texas Retina, our physicians have participated in more than 100 national clinical trials over the past 20+ years, offering our patients access to promising new treatments for a variety of retina conditions, including age-related macular degeneration (AMD), ocular/uveal melanoma (cancer), diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and uveitis.
Conducting ongoing research that advances retinal care is a value that was instilled by the pioneering physicians who founded our practice more than 50 years ago. Over time, this work has helped lead to new sight-saving treatments for diseases that once robbed patients of their vision.
We remain committed to conducting ongoing research that will advance retinal care and recently opened 6 new clinical trials:
Diabetic Macular Edema
- EYE-RES 103 (Arlington, Dallas Main, Fort Worth, Plano) — A randomized, double-masked, multi-center, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal EYE103 compared with intravitreal ranibizumab (0.5 mg) in participants with diabetic macular edema.
- Lotus-2 (Dallas Main) — A Phase 1b/2a study of a novel multivalent fusion antibody (EB-105) in subjects with diabetic macular edema (DME) (LOTUS-2 Study).
Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA)
- Sanofi (Dallas Main) — A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of a one-time intravitreal dose of SAR446597 in participants with geographic atrophy secondary to age-related macular degeneration (AMD).
Retinal Vein Occlusion or Wet Macular Degeneration
- EYE-RES-104 (Dallas Main, Plano) — A Phase 2 randomized, dose-masked study of intravitreal (IVT) EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
Uveal Melanoma
- IDEAYA (Dallas Main) — A randomized, Phase 3, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma.
Uveitis
- Peak/Pinnacle (Plano) — A multi-center platform study on the safety, tolerability, bioactivity, and pharmacokinetics of intravitreal therapies in retinal vascular and inflammatory diseases.
We currently have a total of 22 open studies. Click here to view our actively enrolling clinical trials.
For more information or to determine eligibility for any of these studies, please contact our research department at (214) 692-6885, ext. 1.